How much is Jisandai (Bingtongsha) medical insurance policy and price and how to purchase it?

Epclusa (Epclusa), this oral antiviral drug developed by Gilead Sciences, is specially designed to treat chronic hepatitis C virus (HCV) infection, especially against all genotypes (1-6types) of HCV. Its core ingredients include sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir), the former as NS5B< /span>Polymerase inhibitors can effectively prevent the replication of virusRNA, while the latter, as a NS5A inhibitor, can inhibit virus replication and virus particle assembly. The synergistic effect of these two ingredients makes Jisandai (Bingtonsha) show significant efficacy in the treatment of HCV of different genotypes.

At present, Jisandai (Bingtonsha) has been launched in the Chinese market and has been successfully included in the medical insurance directory, providing patients with a convenient channel to purchase domestically. Its price is relatively affordable, about more than 3,000 yuan. However, specific prices and medical insurance reimbursement policies may vary by region, so patients are advised to consult their local hospital or pharmacy before purchasing to obtain the most accurate information. Compared with the domestic market, generic drugs produced in India and Bangladesh are cheaper, costing only a few hundred yuan, and the main ingredients of these drugs are basically the same as the domestic versions.

Jisandai (Bingtonsha) has excellent performance in the treatment of hepatitis C and is suitable for patients with chronic hepatitis C of all genotypes, regardless of whether they have cirrhosis or not. For patients with decompensated cirrhosis, the combined use of Bingtonsa and Ribavirin can further improve the therapeutic effect. The standard treatment plan is to take one tablet orally every day for 12 weeks. However, for some special cases, the treatment cycle may be appropriately adjusted based on the doctor's recommendations.

Clinical trial data further confirmed the therapeutic effect of Jisandai (Bingtonsha). Its cure rate for HCV patients of various genotypes exceeded 95%, showing a high cure rate (SVR12). Although some minor side effects such as headache, fatigue, and nausea may occur during use, most patients tolerate it. Patients should undergo regular liver function tests during medication and closely monitor the side effects and efficacy of the medication to ensure the safety and effectiveness of the treatment.